Anaptysbio (ANAB) Current Assets (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Current Assets data on file, last reported at $316.1 million in Q1 2026.

• Quarterly Current Assets fell 12.94% year-over-year to $316.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $316.1 million (down 12.94% YoY) and the FY2025 annual result came in at $350.2 million, down 18.9% from the prior year.
• Current Assets declined to $316.1 million in Q1 2026, from $350.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $512.4 million in Q1 2022 to a low of $291.9 million in Q2 2025.
• A 5-year average of $402.7 million and a median of $428.0 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets surged 32.36% — and 2025, when it declined 26.31%.
• Tracing ANAB's Current Assets over 5 years: stood at $447.2 million in 2022, then decreased by 9.03% to $406.8 million in 2023, then gained by 6.16% to $431.9 million in 2024, then dropped by 18.9% to $350.2 million in 2025, then retreated by 9.75% to $316.1 million in 2026.
• The last three Current Assets figures came in at $316.1 million (Q1 2026), $350.2 million (Q4 2025), and $330.6 million (Q3 2025), per Business Quant data.